Next Article in Journal
Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents
Next Article in Special Issue
TMT and PRM Based Quantitative Proteomics to Explore the Protective Role and Mechanism of Iristectorin B in Stroke
Previous Article in Journal
New Copper Complexes with Antibacterial and Cytotoxic Activity
Previous Article in Special Issue
Dihydropyrimidinase-Related Protein 2 Is a New Partner in the Binding between 4E-BP2 and eIF4E Related to Neuronal Death after Cerebral Ischemia
 
 
Review
Peer-Review Record

Multi-Level Biomarkers for Early Diagnosis of Ischaemic Stroke: A Systematic Review and Meta-Analysis

Int. J. Mol. Sci. 2023, 24(18), 13821; https://doi.org/10.3390/ijms241813821
by Qianyun Li 1, Lingyun Zhao 1, Ching Long Chan 1, Yilin Zhang 1, See Wai Tong 1, Xiaodan Zhang 1, Joshua Wing Kei Ho 2, Yaqing Jiao 1 and Timothy Hudson Rainer 1,*
Reviewer 1:
Reviewer 2:
Int. J. Mol. Sci. 2023, 24(18), 13821; https://doi.org/10.3390/ijms241813821
Submission received: 8 August 2023 / Revised: 25 August 2023 / Accepted: 4 September 2023 / Published: 7 September 2023
(This article belongs to the Special Issue Molecular Researches on Ischemic Stroke)

Round 1

Reviewer 1 Report

This is an extremely interesting and well conducted work on early diagnostic circulating biomarkers in ischemic stroke.

But in no way, the dosage of these markers can be presented as an alternative to neuroimaging in the early diagnosis of cerebral stroke.

First of all, neuroimages in acute stroke do not only serve to rule between ischemia and hemorrhage, even within 4.5 hours of onset. They give an infinity of other information, useful for the proper management of the patient in the acute phase.Then, how long is it necessary to get the results of dosages? Are they available 24/24? a single context in which it could possibly be considered would be the LMIC countries.

Hence, even the conclusion is excessively presumptuous.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This is a very large literature review. As such it is vulnerable to errors in the papers reviewed, and this should perhaps be briefly discussed.

The authors seem to assume that blood measures of various metabolites will be useful in clinical management of brain vascular disease, but there is evidence to support this rather remarkable belief. Decisions in clinical management of stroke patients are made in the first  few hours (<5) after onset, so any so-called biomarker must be evident in that tight window. The review does not address this specifically. Imaging is by far the best current "marker" and is likely to remain so.

The authors' so-called biomarkers are metabolic responses to brain vascular events of various types occurring after the event. The review is useful in this sense but not as a diagnostic exercise. It should be rewritten with this in mind. It has biological significance, perhaps.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

Please modify the last sentence of conclusion as follow: hese findings pro- vide a foundation for future research that could have a significant impact on the IS management.

OK for other changes.

 

Back to TopTop